Status:
ENROLLING_BY_INVITATION
Acupoint Application With Herbal Fumigation and Wash for Preventing Diarrhea-induced Perianal Infection in Allo-HSCT Patients
Lead Sponsor:
Ruijin Hospital
Conditions:
Allogeneic Hematopoietic Stem Cell Transplantation
Eligibility:
All Genders
14-70 years
Phase:
NA
Brief Summary
The goal of this clinical trial is to evaluate whether the combination of herbal fumigation and acupoint application can effectively prevent diarrhea in patients undergoing allogeneic hematopoietic st...
Detailed Description
Diarrhea is one of the most common complications following hematopoietic stem cell transplantation (HSCT), with an incidence rate of 50%-70%. During HSCT, high-dose chemotherapy drugs can damage the i...
Eligibility Criteria
Inclusion
- First-time recipient of allogeneic hematopoietic stem cell transplantation.
- Age between 14 and 70 years old, regardless of gender.
- Primary disease type: Hematologic malignancies or aplastic anemia, with no restrictions on disease stage or remission status.
- Transplant type: Matched sibling donor, haploidentical related donor, or unrelated donor.
- Transplant conditioning regimen: Myeloablative, reduced-intensity, or non-myeloablative.
- Informed consent and voluntary participation in this clinical study.
Exclusion
- Presence of intestinal infection within 2 weeks prior to enrollment.
- Previous diagnosis of inflammatory bowel disease or irritable bowel syndrome.
- Pathologically or radiologically confirmed involvement of the primary disease in the intestines.
- ECOG performance status ≥ 2, or presence of organ failure, rendering the patient unable to tolerate allogeneic hematopoietic stem cell transplantation.
- Allergy to the trial medications or physical conditions unsuitable for sitz baths.
- Individuals with mental disorders or those unable to provide informed consent.
- Poor compliance, such as failure to implement the intervention measures for 3 consecutive days.
- HIV-infected individuals, or those with a history of drug abuse or chronic alcoholism that may affect the evaluation of trial results.
Key Trial Info
Start Date :
March 18 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 30 2026
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT06912347
Start Date
March 18 2025
End Date
March 30 2026
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ruijin hospital
Shanghai, Shanghai Municipality, China, 200020